Gene therapy helps patients with hemophilia B

(Medical Xpress) -- An experimental gene therapy technique boosted the production of a vital blood clotting factor in six people with hemophilia B, according to new research supported by the National Institutes of Health. The therapy could give patients a long-term solution for preventing prolonged bleeding episodes and spontaneous bleeding.

People with hemophilia bleed more following trauma than people without the disease, and those with severe disease may bleed spontaneously. patients are unable to produce enough human clotting factor IX, also referred to as FIX, which is essential for normal blood clotting. are the only cells in the body capable of producing a form of factor IX that is active in the clotting process.

The study, funded in part by the NIH's National Heart, Lung, and Blood Institute (NHLBI), involved researchers joining the FIX gene to a virus that targets liver cells. This allowed the normal FIX gene to be delivered using intravenous infusion to the liver cells of patients with hemophilia B. The infusion allowed the patients to produce more FIX. The results will appear online Dec. 10 in the and in the Dec. 22 print edition. The paper will also be presented on Sunday, Dec. 11 at the American Society of Hematology's annual meeting in San Diego.

"Hemophilia has long been one of the disorders thought most likely to be correctible with , but previous approaches to deliver the gene have been disappointing. Results from this study represent a promising step toward making gene therapy a viable treatment option for hemophilia B," said Susan B. Shurin, M.D., acting director of the NHLBI. "If future studies support these findings, it would bring a significant improvement in the quality of life for those living with the disease."

Researchers from the University College London Cancer Institute, and St. Jude Children’s Research Hospital, Memphis, Tenn., led a team that examined the effects of delivering the FIX gene to patients. Scientists inserted the FIX gene into a virus, which served as the delivery vehicle for the gene therapy.

The researchers studied six people with severe hemophilia B who were producing clotting factor IX at less than 1 percent of normal levels before receiving the gene therapy. Prior to enrolling in the study, participants were receiving the standard treatment for severe hemophilia B of infusions of manufactured FIX several times a month.

The FIX gene was packaged in a modified adeno-associated virus, AAV8, which targets liver cells. After receiving the FIX gene therapy, each participant produced FIX at between 2 and 11 percent of normal levels. In the short-term follow-up period (six to 16 months), four of the six participants no longer required FIX infusions for routine bleeding. The other two participants required FIX infusions less frequently than before the study.

The unique feature of this approach is the use of AAV8 to deliver the gene to the appropriate cells. If future studies show that immunologic or other factors do not limit its long-term effectiveness, people with hemophilia B could produce their own FIX and potentially avoid reliance upon FIX infusions. While more work is needed, these results are more promising than prior attempts at gene therapy for the hemophilias.

Hemophilia B is less common than hemophilia A, a deficiency of clotting factor VIII. About 1 in 5 hemophilia patients has hemophilia B, while the other four have hemophilia A. Hemophilia is an inherited condition that affects men more frequently. Worldwide, about 1 in 5,000 men are born with hemophilia A and 1 in 25,000 men are born with B each year.

Provided by National Institutes of Health

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New method boosts blood-clotting for hemophiliacs

Dec 11, 2011

Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated ...

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments